Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-month ARSI discontinuation versus continuation in low-volume mCSPC
NL-OMON58722Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apalutamide and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Erasmus MC. Primary endpoint: Clinical progression-free survival. Started Feb 2024; status: recruiting.
02
Drugs
apalutamideenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON58722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58722.